/Investor DB

NGN NextGen Investment — Full Portfolio

2 tracked investments · listed companies and verified rows first

Hypercell Technologieshypercelltechnologies.cominSep 2026SEC filingmedium confidence

Hypercell develops rapid on-site diagnostic tests that detect pathogens such as Salmonella and E. coli in the food supply chain, aiming to deliver both speed and lab-grade accuracy.

BiotechFoodTechHealthtechMedical DevicesBrookhaven, US

Brian McFarlane(Chief Commercial Officer)inLoïc Deblais(Chief Science Officer)inSam Jactel(Co-founder & Senior Advisor)inBruno Jactel(Founder)inJames Cali(Director)Tony Puri(Director)

Board seatJames Cali· per SEC Form D · $4.4M raise · filed Oct 2026

Co-investorsSerra VenturesSOSV

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

NextGen CCM

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.